OmniAb (OABI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for June 17, 2025, at the corporate headquarters in Emeryville, CA, with a record date of April 23, 2025.
Shareholders will vote on the election of two Class III directors and the ratification of Ernst & Young LLP as the independent auditor for 2025.
Proxy materials are primarily distributed electronically to reduce costs and environmental impact.
Voting matters and shareholder proposals
Proposal 1: Election of Carolyn R. Bertozzi, Ph.D. and John Higgins as Class III Directors for a term expiring at the 2028 Annual Meeting.
Proposal 2: Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.
Shareholder proposals for the 2026 meeting must be received by January 5, 2026, for inclusion in the proxy statement.
Board of directors and corporate governance
Board consists of seven directors, with a majority being independent and all committees fully independent.
Separate roles for Board Chair and CEO; annual self-evaluations and CEO evaluation by independent directors.
Committees: Audit, Human Capital Management and Compensation, Nominating and Corporate Governance, and Science and Technology, each with defined charters and responsibilities.
Stock ownership guidelines and a Code of Business Conduct and Ethics are in place.
Board composition includes two female and five male directors, with a focus on diverse backgrounds and expertise.
Latest events from OmniAb
- Over 400 active programs and new technology launches drive growth and future cash flow.OABI
Corporate presentation24 Mar 2026 - 107 partners, 407 programs, new platforms, and 2026 revenue growth expected.OABI
Q4 20254 Mar 2026 - Q2 revenue up 10% to $7.6M, net loss narrowed, and partnerships and cash remain strong.OABI
Q2 20242 Feb 2026 - Expanding partnerships and innovative antibody platforms drive growth and long-term royalties.OABI
Jefferies Global Healthcare Conference31 Jan 2026 - Q3 revenue fell to $4.2M, but partner and program growth and $59.4M cash support future progress.OABI
Q3 202414 Jan 2026 - Double-digit partner and program growth, Q4 revenue up, 2025 revenue seen at $20–$25M.OABI
Q4 202424 Dec 2025 - Resale registration covers 21.25M shares from a $30M private placement; no proceeds to company.OABI
Registration Filing16 Dec 2025 - OmniUltra enables novel antibody and peptide discovery, targeting a trillion-dollar market.OABI
Investor Update16 Dec 2025 - Votes will be held on two director nominees and auditor ratification at the June 2025 meeting.OABI
Proxy Filing2 Dec 2025